[email protected]   +1 (304) 306-0723

Y-mabs’ Danyelza for R/R High-Risk Neuroblastoma: Business & Launch Strategies

Danyelza High risk Neuroblastoma Launch Strategy

The Y-mabs’ antibody candidate naxitamab-gqgk (Danyelza) for the treatment of high-risk neuroblastoma was recently approved by the FDA. This approval is subject to naxitamab-gqgk (Danyelza) for the treatment of pediatric patients aged 1 year and […]

Read More

Get In Touch

Let's keep the conversation going